This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

10/15/12 - 06:00 AM EDT

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

read more >
Sarepta Shares Still Have Upside Sarepta Shares Still Have Upside

10/03/12 - 10:43 AM EDT

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

read more >
Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

10/01/12 - 07:30 AM EDT

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

read more >
A New Reason to be Bullish About Sarepta Therapeutics A New Reason to be Bullish About Sarepta Therapeutics

09/24/12 - 07:00 AM EDT

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

read more >
Idenix Pharma: Guilty By Association Idenix Pharma: Guilty By Association

09/21/12 - 07:48 AM EDT

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

read more >
Bull Case on Peregrine Pharma Shouldn't Be Dismissed Bull Case on Peregrine Pharma Shouldn't Be Dismissed

09/17/12 - 09:33 AM EDT

Believers in Peregrine's lung cancer drug bavituximab state their case.

read more >
Peregrine Pharma: Not Good Enough to Own, Too Risky to Short Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

09/10/12 - 11:53 AM EDT

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

read more >
More Reasons to Invest in Sarepta With Caution More Reasons to Invest in Sarepta With Caution

08/27/12 - 10:35 AM EDT

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

read more >
Sarepta's Risks Shouldn't Be Ignored Sarepta's Risks Shouldn't Be Ignored

08/21/12 - 07:00 AM EDT

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

read more >
In These Turbulent Times, Reach for Merck In These Turbulent Times, Reach for Merck

08/13/12 - 09:03 AM EDT

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.

read more >
Page 2 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs